The first HSP90 inhibitor, 17-AAG, an analog of geldanamycin was conducted in several clinical phase I and II trials for the treatment of patients with solid tumors and HER2-positive breast cancers [23,44]. This evidence concerns the gene ERBB2 and breast cancer.